Advertisement

Topics

DS-8201a Efficacious in Breast Cancer Across Varying HER2 Levels

12:08 EDT 13 Jun 2018 | OncLive

Long-term findings from a phase I study of trastuzumab deruxtecan showed that the investigational HER2-targeting antibody-drug conjugate had antitumor activity in multiple tumor types that expressed HER2 at varying levels. 

Original Article: DS-8201a Efficacious in Breast Cancer Across Varying HER2 Levels

NEXT ARTICLE

More From BioPortfolio on "DS-8201a Efficacious in Breast Cancer Across Varying HER2 Levels"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...